Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.43 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | BRS3 | P32247 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | GPR52 | Q9Y2T5 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4993145 | 0.92 | FAAH (0.47) | KDM4EALDH1A1GAALMNAPARP1 | |
| SCHEMBL4983033 | 0.88 | GRM2 (0.41) | KDM4EALDH1A1PARP1GRM2 | |
| SCHEMBL4988838 | 0.87 | GRM2 (0.47) | KDM4EALDH1A1GRM2FAAHSIGMAR1 | |
| SCHEMBL4993429 | 0.86 | DRD4 (0.42) | GRM2GPR52DRD4 | |
| SCHEMBL4986124 | 0.85 | CLPP (0.42) | KDM4EALDH1A1PARP1GRM2FAAH | |
| SCHEMBL4993338 | 0.85 | CLPP (0.42) | KDM4EGAAGRM2FAAHSIGMAR1 | |
| SCHEMBL4986167 | 0.85 | GRM2 (0.41) | KDM4EALDH1A1LMNAPARP1GRM2 | |
| SCHEMBL4984714 | 0.85 | KMT2A (0.44) | KDM4EALDH1A1GAAPARP1ADORA1 | |
| SCHEMBL4989419 | 0.84 | GPR142 (0.43) | GPR52 | |
| SCHEMBL4988919 | 0.84 | C5AR1 (0.38) | GRM2C5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | KDM4E 4128/4885ALDH1A1 3640/4885GAA 4179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.